Kalıtsal Trombofilili Gebelerin Obstetrik ve Neonatal Sonuçları

GİRİŞ ve AMAÇ: Bu çalışmada kalıtsal trombofili tanısıylatedavi alan gebelerin obstetrik ve neonatal sonuçlarınındeğerlendirilmesi amaçlandı. YÖNTEM ve GEREÇLER: 2018-2019 tarihlerinde kadınhastalıkları ve doğum kliniğine başvuran gebelik öncesindekalıtsal trombofili tanısı alıp tedavisi (asetilsalisilik asit vedüşük moleküler ağırlıklı heparin) başlanan ve sonrasındagebe kalan 56 gebe çalışma grubunu, obstetrik veya fetalgelişimi etkileyebilecek sistemik hastalığı olmayan 79 sağlıklıgebe ise kontrol grubunu oluşturdu. Veriler retrospektif olarakkayıtların taranmasıyla elde edildi. Her iki grubun demografiközellikleri (yaş, parite, vücut kitle indeksi, eğitim düzeyleri),obstetrik sonuçları (doğum haftası, doğum kilosu, pretermeylem oranı, düşük doğum ağırlığı oranı, doğum şekli) veneonatal sonuçları (1. ve 5. dakika apgar skorları, neonatalyoğun bakım yatış oranları) karşılaştırıldı. BULGULAR: Grupların demografik özellikler açısındandağılımı homojendi (p>0,05). Gruplar arasında ortalamadoğum kilosu, doğum haftası, 1. dakika apgar değerleri,preterm eylem ve neonatal yoğun bakım yatış oranlarıaçısından fark yoktu (p>0,05). Ancak düşük doğum ağırlıklıbebek sayıları, 5. dakika apgar skorları ve doğum şekilleriaçısından gruplar arasında anlamlı fark mevcuttu. Kalıtsaltrombofili grubunda kontrol grubuna kıyasla, düşük doğumağırlıklı bebek, preeklampsi ve sezeryan oranları daha fazla, 5.dakika apgar skorları daha düşüktü (p

Obstetric and Neonatal Results of Pregnant Women withHereditary Thrombophilia

INTRODUCTION: To evaluate the obstetric and neonataloutcomes of pregnant women treated for hereditarythrombophilia. METHODS: Fifty-six pregnant women who were admitted tothe gynecology and obstetrics clinic between 2018 and 2019,diagnosed as having hereditary thrombophilia beforepregnancy, and whose treatment (acetylsalicylic acid and lowmolecular weight heparin) began at pregnancy comprised thestudy group, and 79 healthy pregnant women without systemicdisease that might affect obstetric or fetal developmentconstituted the control group. Study data were obtainedretrospectively by scanning hospital records. Demographiccharacteristics of both groups (age, parity, body mass index,education level), obstetric results (birth week, birth weight,preterm labor rate, low birth weight rate, delivery type) andneonatal results (1st and 5th minute Apgar scores, neonatalintensive care hospitalization rates) were compared. RESULTS: The distribution of the groups in terms ofdemographic characteristics was homogeneous (p>0.05).There was no difference between the groups in terms of meanbirth weight, birth week, 1st minute Apgar scores, pretermlabor, and neonatal intensive care hospitalization rates (p>0.05). However, there was a significant difference between thegroups in terms of low birth weight infants, 5th minute Apgarscores, and type of delivery. In the hereditary thrombophiliagroup, low birth weight infants, preeclampsia, and cesareanrates were higher compared with the control group, and the5th minute Apgar scores were lower (p

PDF

___

1.Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995; 90: 725-7.
2.Hossain N, Paidas MJ. Inherited thrombophilia: diagnosis and anticoagulation treatment in pregnancy. Clin Lab Med. 2013; 33: 377-90.
3.Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999; 340: 9-13.
4.Howley HEA, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol. 2005; 192: 694-708.
5.Rodger MA, Walker MC, Smith GN, Wells PS, Ramsay T, Langlois NJ, et al. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol. 2005; 192: 694-708.
6.ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy. Obstet Gynecol. 2013; 122: 706-17.
7.Simcox LE, Ormesher L, Tower C, Greer IA. Thrombophilia and Pregnancy Complications. Int J Mol Sci. 2015; 16: 28418-28.
8.Greer IA, Brenner B, Gris JC. Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? Br J Haematol. 2014; 165: 585-99.
9.Brenner B. Clinical management of thrombophiliarelated placental vascular complications. Blood. 2004; 103: 4003-9.
10.Gerhardt A, Scharf RE, Greer IA, Zotz RB. Hereditary Risk Factors for Thrombophilia and Probability of Venous Thromboembolism During Pregnancy and the Puerperium. Blood. 2016; 128: 2343- 2349.
11.Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy and prevention of thrombosis. 9th ed: College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:e351S–418S.
12.Dugalić S, Petronijevic M, Stefanovic A, Jeremic K, Petronijevic SV, Soldatovic I, et al. The association between IUGR and maternal inherited thrombophilias: A case-control study. Medicine. 2018; 97: e12799.
13.Livrinova V, Lega MH, Dimcheva AH, Samardziski I, Isjanovska R. Factor V Leiden, Prothrombin and MTHFR Mutation in Patients with Preeclamsia, Intrauterine Growth Restriction and Placental Abruption. Open Access Maced J Med Sci. 2015; 3: 590-4.
14.Hoffmann E, Hedlund E, Perin T, Lyndrup J. Is thrombophilia a risk factor for placenta-mediated pregnancy complications? Arch Gynecol Obstet. 2012; 286: 585-9.
15.Hemsworth EM, O'Reilly AM, Allen VM, Kuhle S, Brock JAK. Association Between Factor V Leiden Mutation, Small for Gestational Age, and Preterm Birth: A Systematic Review and Meta-Analysis. J Obstet Gynaecol Can. 2016; 38: 897-908.
16.Uvuz F, Kilic S, Yilmaz N, Tuncay G, Cakar E, Yuksel B, et al. Relationship between preterm labor and thrombophilic gene polymorphism: A prospective sequential cohort study. Gynecol Obstet Invest. 2009; 68: 234-8.
17.Wang X, Bai T, Liu S, Pan H, Wang B. Association between thrombophilia gene polymorphisms and preeclampsia: a meta-analysis. PLoS One. 2014; 9:e100789.
18.Baptista FS, Bortolotto MRFL, Bianchini FRM, Krebs VLJ, Zugaib M, Francisco RPV. Can thrombophilia worsen maternal and perinatal outcomes in cases of severe preeclampsia? Pregnancy Hypertens. 2018; 11: 81-86.
19.Arachchillage DRJ, Mike Makris M. Inherited Thrombophilia and Pregnancy Complications: Should We Test? Semin Thromb Hemost. 2019; 45: 50-60.